Additional clinical benefit is the key value message of manufacturers. Payers often have a different definition and perception of clinical value. In addition payers are gaining influence on both decision makers and providers. This may lead to a delay of market access and market uptake.
Access to and communication with payers is crucial. However, there are barriers!
pharmaLevers is helping clients to overcome these barriers by:
facilitating access to payers
delivering payer insights
delivering messages that are addressing payers key concerns directly
design and implement new ways to marketing drugs to payers
Are the pricing models and managed entry agreements (MES) used for the twenty best-selling drugs of 2019 sustainable and expedient for the Swiss healthcare system? What further optimizations would be necessary to dampen the cost development?